Bio-Thera Solutions, Ltd.

SHSE:688177 Stock Report

Market Cap: CN¥10.0b

Bio-Thera Solutions Past Earnings Performance

Past criteria checks 0/6

Bio-Thera Solutions has been growing earnings at an average annual rate of 16.9%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 34.9% per year.

Key information

16.9%

Earnings growth rate

21.7%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate34.9%
Return on equity-44.6%
Net Margin-45.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Optimistic Investors Push Bio-Thera Solutions, Ltd. (SHSE:688177) Shares Up 44% But Growth Is Lacking

Oct 09
Optimistic Investors Push Bio-Thera Solutions, Ltd. (SHSE:688177) Shares Up 44% But Growth Is Lacking

Time To Worry? Analysts Just Downgraded Their Bio-Thera Solutions, Ltd. (SHSE:688177) Outlook

Sep 05
Time To Worry? Analysts Just Downgraded Their Bio-Thera Solutions, Ltd. (SHSE:688177) Outlook

Bio-Thera Solutions, Ltd. (SHSE:688177) Shares May Have Slumped 30% But Getting In Cheap Is Still Unlikely

Jun 06
Bio-Thera Solutions, Ltd. (SHSE:688177) Shares May Have Slumped 30% But Getting In Cheap Is Still Unlikely

Some Confidence Is Lacking In Bio-Thera Solutions, Ltd. (SHSE:688177) As Shares Slide 27%

Apr 18
Some Confidence Is Lacking In Bio-Thera Solutions, Ltd. (SHSE:688177) As Shares Slide 27%

Subdued Growth No Barrier To Bio-Thera Solutions, Ltd. (SHSE:688177) With Shares Advancing 30%

Mar 04
Subdued Growth No Barrier To Bio-Thera Solutions, Ltd. (SHSE:688177) With Shares Advancing 30%

Revenue & Expenses Breakdown

How Bio-Thera Solutions makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688177 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24825-378255758
30 Jun 24792-378228751
31 Mar 24711-371211709
31 Dec 23705-395201769
30 Sep 23534-607187804
30 Jun 23541-565189770
31 Mar 23536-513184705
31 Dec 22455-480174616
30 Sep 22803-62191593
30 Jun 22737-90201582
31 Mar 2285081210549
31 Dec 2183782216543
30 Sep 21492-263221539
30 Jun 21463-267209546
31 Mar 21223-513181594
31 Dec 20183-513164563
30 Sep 20106-501115522
30 Jun 2049-55186529
31 Mar 2020-60071567
31 Dec 191-1,023401637
30 Sep 191-1,0754081,053
31 Dec 180-55326542
31 Dec 172-23612237
31 Dec 163-13711132

Quality Earnings: 688177 is currently unprofitable.

Growing Profit Margin: 688177 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688177 is unprofitable, but has reduced losses over the past 5 years at a rate of 16.9% per year.

Accelerating Growth: Unable to compare 688177's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 688177 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).


Return on Equity

High ROE: 688177 has a negative Return on Equity (-44.57%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies